Kidney Disease FAQ's
LIPOSORBER® is indicated for use in the treatment of pediatric and adult patients with nephrotic syndrome associated with primary FSGS when:
- Standard treatment options, including corticosteroids and/or calcineurin inhibitors, are unsuccessful or not well tolerated and the patient’s glomerular filtration rate (GFR) > 60ml/min/1.73 m2 or
- the patient is post renal transplantation.
On average, the entire procedure is completed in 2-4 hours. At all times, less than a pint of your blood and plasma will be circulating through the LIPOSORBER® treatment machine.
During the procedure, the plasma is separated from the whole blood and the bad LDL cholesterol and Lp(a) are removed from the plasma. Then the plasma and blood are recombined, warmed and returned back to you.
The LIPOSORBER® consists of disposable components and an automated computer machine that controls and monitors you each step of the way.
There are more than 50 locations across the United States and Canada that offer LIPOSORBER® treatment with new facilities added regularly.
LIPOSORBER® received FDA approval in 1996. It has been in worldwide use since 1986 with more than 600,000 LIPOSORBER® treatments performed on over 6,000 patients.
The most common adverse events are hypotension (0.8%), nausea/vomiting (0.5%), and flushing/blotching (0.4%). Other adverse reactions include angina/chest pain, shortness of breath, fainting, lightheadedness and anemia.
For complete safety information, including adverse events and additional contraindications, please visit:
www.accessdata.fda.gov/cdrh_docs/pdf17/H170002D.pdf
Find out more about coverage for LIPOSORBER®
